He Lijing, vice president of GSK of "medical fast reading society", decided to leave 5 varieties for priority review

As of 24:00 on February 3, 20438 cases have been confirmed nationwide; huoshenshan hospital has received the first batch of patients; 10 departments have jointly cracked down on illegal wildlife trading, illegal production and sale of protective products such as masks; he Lijing, vice president of GSK, has decided to leave; gene therapy new upstarts plan to raise 125 million US dollars through IPO As of 24:00 on February 3, the national health and Health Commission has received 20438 confirmed cases (2 cases deducted from Heilongjiang Province) reported by 31 provinces (autonomous regions, municipalities directly under the central government) and Xinjiang production and Construction Corps, 2788 serious cases, 425 deaths, 632 discharged cases cured and 23214 suspected cases (official website of National Health Commission) On February 2, the General Administration of market supervision, together with the central network information office, the Ministry of ecological environment, the Ministry of agriculture and rural areas, the Ministry of public security, the Ministry of Commerce, the health and Health Commission, the General Administration of customs, the forestry and grass administration, the drug administration and other ministries (bureaus) held a special law enforcement action deployment meeting to combat illegal trade in wild animals and illegal sales of masks and other protective products (General Administration of market supervision) Novel coronavirus, a new type of coronavirus in Wuhan, was stationed in the 1400 pneumonia hospital of the army on the 2 day After that, medical supplies, infection control, rules and regulations were prepared At 9:26 today, huoshenshan hospital began to accept the first batch of patients, who were from three hospitals, including Wuchang hospital and Hankou hospital Wuhan emergency center is responsible for the transfer task, and the transfer vehicles are all negative pressure ambulances (voice of China, CCTV) On February 3, GSK announced to employees that he Lijing, vice president of GSK and head of China's prescription drug R & D and medical affairs department, had decided to leave and seek external career development opportunities The last working day was February 10 Before joining GSK, he Li Jing used to be the head of medical affairs of Novartis in China In March 2018, he joined GlaxoSmithKline China as the head of medical affairs (medical representative) Today, passage bio, a gene therapy company, announced plans to raise $125 million in an IPO Last year, the company completed two rounds of financing of $225 million to develop its treatment drugs for rare single gene central nervous system diseases (chuangjianhui) Today, Rani therapeutics, a California based company, announced that it has outperformed expectations in 58 trials of ranipill, a delivery capsule for biological macromolecules Mr Mir Imran, the company's chief executive, said in an interview that with the acceleration of clinical development of ranipill, Rani needs financial support and is expected to have an IPO within one year (chuangjianhui) AstraZeneca recently announced that the phase III Thales trial to evaluate the cardiovascular prognosis of the anticoagulant brilinta (ticagrel) reached the primary end point The results showed that the combination of brilinta and aspirin reduced the combined risk of stroke and death compared with aspirin alone (Biovalley) Today, seqirus announced that the U.S FDA approved the launch of its adjuvant monovalent influenza A (H5N1) vaccine audenz to prevent people from contracting influenza A (H5N1) for six months or more According to the company's press release, audenz is the first cell-based adjuvant influenza A (H5N1) vaccine approved by the FDA, which aims to improve the protection against this type of influenza when pandemic influenza occurs (yaomingkant) Today, resurlogix announced that the US FDA has granted its apabetalone (rvx-208) breakthrough therapy certification to treat major unconscionable vascular events caused by type 2 diabetes and acute coronary syndrome as a secondary preventive therapy in combination with standard care methods (including high-intensity statins) (yaomingkant) On March 3, CDE plans to add 8 new announcements for priority evaluation of varieties, involving 5 varieties and 4 pharmaceutical companies, including 2 children's drugs and 3 rare disease drugs Among them, enalapril maleate oral solution of Henan Lantian Pharmaceutical Co., Ltd and baclofen injection of Nanjing Haina Pharmaceutical Co., Ltd are all proposed to be included in the priority review on the basis of "6 types of children's drugs" (meter net) Recently, the FDA approved armune therapeutics (aimt) company's ar101 for immunotherapy of peanut allergy in 4-17-year-old children and adolescents The trade name is palforzia ®, which means that the first peanut allergy immunotherapy has been officially approved (CPHI Pharma online) Recently, the FDA approved tazemetostat, the "first in class" EZH2 inhibitor developed by epizyme company, to be put on the market for the treatment of non operative, metastatic or locally advanced epithelioid sarcoma (medicine crossing) Recently, Geneyork Pharmaceutical Co., Ltd and Lannett Pharmaceutical Co., Ltd of the United States began to jointly sell 1 mg, 2.5 mg, 5 mg, 10 mg, 20 mg, and 50 mg generic prednisone tablets in the United States market in a total of 6 specifications The drug is a kind of hormone drug, mainly used in allergic and autoimmune inflammatory diseases (American news agency) AGC biology and trefoil therapeutics, the global biopharmaceutical contract development and production agency, announced a production contract to supply its main product, tthx1114 Trefoil is developing fgf-1-based products in this engineering form to restore vision of patients with corneal diseases by regenerating corneal tissue (American news agency)